跳转至内容
Merck
CN
  • Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms.

Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms.

Archives of virology (2015-02-18)
Qihua Ling, Jianjie Chen, Hua Zhou, Jun Zhong, Yiyun Chen, Qingyan Ye, Yunhui Zhuo, Niehong Min, Binyi Shang
摘要

Although the single-nucleotide polymorphism (SNP) rs12979860 in the IL28B gene is a better predictor of sustained virological response to treatment of chronic hepatitis C (CHC) than other baseline factors, some CHC patients with the favorable C allele cannot achieve a sustained virological response when treated with peginterferon plus ribavirin. The aim of this study was to examine baseline factors as predictors of rapid virological response (RVR) and complete early virological response (cEVR) to peginterferon alfa-2a plus ribavirin treatment in Chinese CHC patients with hepatitis C virus (HCV) genotype 1b, with emphasis on the difference between the rs129860 CC and CT/TT genotypes. A total of 337 treatment-naïve patients participated in this study. All patients were treated with peginterferon alfa-2a plus ribavirin at standard dosage. Serum samples from all patients were collected at baseline, week 4, and week 12 for testing of laboratory parameters, and IL28B genotypes were determined. Multivariate analysis showed that among rs12979860 CC genotype patients, glucose level and aspartate amino transferase (AST) activity were inversely associated with RVR, while abnormal platelet count and allergy inversely associated with cEVR. Among rs12979860 CT genotype patients, age below 40 years and short infection duration were associated with RVR, while age below 40 years, short infection duration, high body mass index (BMI), and no history of allergies were associated with cEVR. The baseline factors associated with the response to CHC treatment may depend on the IL28B genotype. Refinement of the baseline predictors based on IL28B genotypes may be useful for management of HCV infection.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
乙醇,Pure 200纯度, Molecular Biology
Sigma-Aldrich
纯乙醇, 200 proof, ACS reagent, ≥99.5%
Sigma-Aldrich
纯乙醇, 200 proof
Sigma-Aldrich
纯乙醇, 200 proof, meets USP testing specifications
Sigma-Aldrich
纯乙醇, 200 proof, anhydrous, ≥99.5%
Sigma-Aldrich
乙醇,Pure 190纯度, for molecular biology
Sigma-Aldrich
纯乙醇, 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
酒精, BioUltra, Molecular Biology, ≥99.8%, (absolute alcohol, without additive, A15 o1)
Supelco
无水乙醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
纯乙醇, 190 proof, meets USP testing specifications
Sigma-Aldrich
酒精, purum, fine spirit, denaturated with 4.8% methanol, F25 METHYL1, ~96% (based on denaturant-free substance)
Supelco
酒精, standard for GC
Sigma-Aldrich
酒精, puriss. p.a., absolute, ≥99.8% (GC)
Supelco
Ethanol 溶液, certified reference material, 2000 μg/mL in methanol
Sigma-Aldrich
酒精, tested according to Ph. Eur.
Supelco
10% (v/v) 乙醇标准品, 10 % (v/v) in H2O, analytical standard
Sigma-Aldrich
利巴韦林, antiviral
Sigma-Aldrich
80% v/v 乙醇固定液, suitable for fixing solution (blood films)
Sigma-Aldrich
纯乙醇, 190 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
Sigma-Aldrich
纯乙醇, 200 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
Sigma-Aldrich
酒精, absolute, sales not in Germany, ≥99.8% (vol.)
Sigma-Aldrich
纯乙醇, 160 proof, Excise Tax-free, Permit for use required
利巴韦林, European Pharmacopoeia (EP) Reference Standard